# The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

> **NCT03743376** · PHASE2 · COMPLETED · sponsor: **United BioPharma** · enrollment: 31 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **BIOLOGICAL:** UB-421(25 mg/kg) Q2W
- **BIOLOGICAL:** UB-421(25 mg/kg) Q4W

## Key facts

- **NCT ID:** NCT03743376
- **Lead sponsor:** United BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-12
- **Primary completion:** 2020-10-15
- **Final completion:** 2021-12-31
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-05-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03743376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03743376, "The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03743376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*